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Summary 
It has been suggested that neutrophils may be involved in the late-phase reaction of immunoglobulin 
E (IgE)-dependent hypersensitivity states. However, the identity of neutrophil-associated molecules 
inducing the release of mediators  remains undear. In this report, we demonstrate that human 
neutrophils from normal donors or from patients with inflammatory disorders could bind myeloma 
IgE proteins, especially  after desialylation. Northern blot, immunoprecipitation, and flow cytometry 
analyses revealed that neutrophils did not express FceRII/CD23, but rather Mac-2/e binding 
protein (BP), belonging to the S-type lectin family. Similarly to IgA used as positive control, 
myeloma IgE proteins, as well as polyclonal IgE antibodies with or without antibody specificity, 
were both capable of inducing a neutrophil respiratory burst. Anti-Mac-2 but not anti-CD23 
mAb strongly decreased the IgE-dependent activation of neutrophils, induced either by the specific 
antigen or by anti-IgE antibodies. These findings open new perspectives on the functional role 
of neutrophils in IgE-associated diseases including allergic states or parasitic infections. 
I 
nflammatory reactions generally involve  a vast array of medi- 
ators and a variety of effector cells such as mast cells, mac- 
rophages, eosinophils, platelets, and neutropb.ils. Among them, 
neutrophils have been rather neglected in studies concerning 
allergic diseases, although an increase in neutrophil numbers 
and activity was found to be correlated to airway hyperrespon- 
siveness in asthmatic patients (1). These findings have sug- 
gested that neutrophils might play a role in allergic diseases 
characterized by a marked elevation of serum IgE, such as 
asthma,  especially during the late-phase reaction. However, 
neutrophils represent the only blood cell population that does 
not seem to express conventional  Fc receptors for IgE, nei- 
ther FceRI, like basophils or mast cells (2), nor FceRII, like 
macrophages, eosinophils, or platelets (3). Besides these IgE 
Fc receptors, a new family of IgE-binding molecules has been 
recently described. They belong to S-type lectins with the 
ability to bind IgE through carbohydrate recognition domain 
(4). Members of the family include Mac-2/eBP,  which are 
endogenous soluble lectins and can be expressed by various 
cell types (5, 6). One feature of eBP molecules is their re- 
stricted recognition by specific glycoforms of IgE. It is in- 
teresting that the majority of myeloma IgE proteins and poly- 
donal IgE from some patients are able to bind to eBP only 
after desialylation (5, 7). In this respect, it has to be men- 
tioned that the few IgE binding assays previously reported 
on human neutrophils (8, 9) have been performed with my- 
eloma IgE proteins, and therefore did not allow us to inves- 
tigate the existence of functional interactions between neu- 
trophils  and IgE antibodies  from patients.  The wide cell 
distribution of Mac-2/eBP molecules and their recent demon- 
stration  in eosinophils from hypereosinophilic patients  (10) 
led us to investigate their possible existence in human neu- 
trophils. 
Materials and Methods 
NeutrophilPre~rations.  Patient  neutrophils were obtained from 
the venous  blood of patients with various  diseases (allergic  diseases, 
parasitic infections, and eosinophilic disorders) by centrifugation 
through metrizamide  discontinuous  gradients, according  to previ- 
ously described techniques  (11), and coUected  in the lower density 
layer (layer II) corresponding to 20-22% metrizamide solutions. 
Neutrophils from normal blood donors were  isolated by the same 
technique  or by dextran sedimentation,  followed  by centrifugation 
through a cushion of FicoU-Hypaque  (Pharmacia  Fine Chemicals, 
Piscataway, NJ) and hypotonic  lysis to remove  remaining erythro- 
cytes (12). The degree of purity (up to 97.5%) and the morpho- 
logic integrity of cell populations were estimated after staining of 
cytocentrifuged  preparations with Giemsa. Contamination by eo- 
sinophils in neutrophll preparations was <10%. As control, human 
alveolar macrophages were  obtained by bronchoalveolar  lavage of 
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A. Capron, and M. Capron, manuscript  submitted for publication). 
Immunoglobulins,  Antibodies,  and  Antigens.  Human myeloma 
IgE-PS was kindly donated by Dr. H. L. Spiegelberg (School of 
Medicine, University of California, San Diego, CA) and IgE-BL 
was purchased from Bemett Laboratories  (Buena  Park, CA). Human 
sera from patients with hyper-IgE syndrome (25,000 IU/ml) were 
obtained from Dr. F.-T. Liu (The Scripps Research Institute, La 
JoUa, CA). Human sera from patients infected with the parasite 
Schistosoma mansoni were provided by Dr. P. Desreumaux (Centre 
Hospitalier St. Louis, St. Louis, Srnrgal). Serum IgA was obtained 
from Sigma Chemical Co. (St. Louis, MO). The anti-Mac-2 hy- 
bridoma superuatant, previously  described (13), a kind gift of Dr. 
B. Cherayil (MGH Cancer Research, Boston, MA) and irrelevant 
anti-S, mansoni hybridoma supernatant have been used at different 
dilutions in the various assays. Anti-CD23 mAb (8-30) directed 
against the IgE binding domain of CD23 (14) was donated by Dr. 
Suemura (Osaka University Hospital, Osaka, Japan). FITC-labeled 
anti-human  IgE, anti-human IgA, anti-rat IgG, or anti-mouse 
IgM antibodies (Fab 2') were  purchased from Cappel Laboratories 
(Cochranville, PA). Unlabeled anti-human IgE and anti-human 
IgA antibodies  were obtained  from Immunotech (Marseille, France). 
The recombinant  antigen Sm28GST from S. mansoni (15) was kindly 
given by F. Trottein (CIBP, Institut Pasteur). 
Northern Blot Analysis.  Total  tLNA was isolated from neutro- 
phil populations and was subjected to electrophoresis  in a formal- 
dehyde/1.2% agarose gel, blotted onto a nylon filter, and succes- 
sively hybridized overnight at 42~  with ~2P-labeled CD23 (16), 
Mac-2 cDNA (6), and fl-actin probes. Probes were removed by 
boiling the blot on a 0.1% SDS solution, and washes were carried 
out in lx  SSC, 0.05%  SDS at 55~ 
Labeling of Leukocytes and Iraraunoprecipitations.  The cells were 
lysed with a nonionic/detergent mixture and cell extracts were io- 
dinated with t2sI as previously  described (Truong et al., manuscript 
submitted  for  publication).  Aliquots  of 2  x  106  cpm  radio- 
iodinated  cell extracts were precleared  for 2 h with normal rat serum 
and 50 #1 of protein G-Sepharose (Pharmacia Fine Chemicals) in 
TNSTEN (50 mM Tris-HC1 pH 8.2, 500 mM NaCt, 0.1% SDS, 
0.5% Triton-X 100, 5 mM EDTA, 0.02% NAN3) with 0.1% aproti- 
nine. Immunoprecipitation was carried out by adding anti-Mac-2 
hybridoma supernatant (1:10 final dilution) followed by 50 IA of 
protein  G-Sepharose. After  overnight  incubation  at  4~  the 
Sepharose beads were washed 10 times with TNSTEN, 0.1% aproti- 
nine, and then resuspended and boiled for 3 min in 40/A of lx 
SDS-PAGE sample buffer. Aliquots of released material were ana- 
lyzed by SDS-PAGE. 
Flow Cytometry.  For the detection of surface Mac-2, 106 neu- 
trophils were incubated with anti-Mac-2 or control anti-S, raan- 
soni supernatants at a final dilution of 1:10 in PBS for 1 h at 4~ 
For IgE and IgA binding analysis,  nentrophils were incubated with 
50 t~g/ml of myeloma IgE (IgE-PS or IgE-BL) or serum IgA for 
1 h at 4~  In some experiments, myeloma IgE proteins or IgA 
have been incubated with untreated or heat-inactivated  neuramini- 
dase (Clostridiura  perfringens type, 0.5 U/rag of  protein, Sigma  Chem- 
ical Co.) for 90 rain at 37~  before binding to nentrophils. For 
the detection of  CD23, neutrophils were incubated with 50/~g/ml 
mAb 8-30 or control IgM mAb for 1 h at 4~  In all experiments, 
after  washing  with PBS, cells  were incubated  with the corresponding 
FITC-conjugated anti-Ig antibodies (1:40 final dilution) for 30 min 
at 4~  After washing, cells  were fixed  with 1% paraformaldehyde 
and analyzed with an Orthocytofinorograph (modal 50H; Ortho 
Diagnostics Systems,  Westwood, MA) using a logarithmic fluores- 
cence intensity scale. Results are expressed as a percentage of la- 
beled neutrophils after subtraction of the background fluorescence 
obtained with isotype controls, similarly to techniques reported 
for eosinophils (17). 
Neutrophil  Activation.  Neutrophils  (2.5  x  10~/ml) were in- 
cubated with 10/~g/ml myeloma  IgE proteins, serum IgA, or with 
medium for 30 min at 4~  Anti-IgE or anti-IgA antibodies (25 
/~g/ml) were then added, respectively.  Experiments also have been 
performed with polyclonal  IgE present in serum from S. mansoni- 
infected  patients, and further stimulation with the specific  antigen 
(recombinant Sm28GST) (15) or with antiqgE. Sera from patients 
with hyper-IgE syndrome also have been used to activate neutro- 
phils. The respiratory  burst after activation was evaluated  by a che- 
miluminescence (CL) procedure in the presence of luminol (250 
/~g/ml). Light emission  was monitored after 15-30 min of incuba- 
tion at 37~  using a photometer (Nucleotimetre  107; Interbio CLV, 
Villeurbanne, France) and was expressed in mV (100 CL U  =  1 
mV). For inhibition experiments, anti-Mac-2  or control hybridoma 
supernatants and anti-CD23 or control mAb were added at var- 
ious concentrations together with IgE or serum before addition 
of anti-IgE antibodies or antigen. 
Statistical Analysis.  Student's t test for unpaired and paired ex- 
periments, and correlation analysis  have been used. 
Results and Discussion 
Detection of mRNA  Encoding Mac-2/eBP.  The existence 
of IgE-binding molecules such as FceRII/CD23 or Mac-2/eBP 
in  purified  human  neutrophils  was  first  investigated  by 
Northern blot  (Fig.  1).  Neutrophil RNA extracted from 
different donors was first probed with the cDNA encoding 
CD23.  No apparent mRNA band was detected at the ex- 
pected 1.7-kb  size. The same Northern blot was then hy- 
bridized with the Mac-2 cDNA probe. Neutropb.ils from both 
normal donors (Fig. 1, lanes 1 and 2) or patients (Fig. 1, lanes 
3-5)  expressed  the 1.2-kb  mRNA corresponding to Mac- 
2/heBP. Neutrophils purified from some patients (Fig. 1, lanes 
4 and 5) appeared  to express higher amounts of Mac-2/eBP 
mRNA than neutrophils purified from other patients or from 
normal donors. These findings seem in agreement with the 
variable levels of S-type lectin expression during cell differen- 
Figure 1.  Northern blot analysis of neutrophil RNA prepared from 
normal donors (lanes I and 2) and from three patients  with allergic  dis- 
eases (lanes  3-5). The blot was successively  hybridized  with  CD23, hMac-2, 
and fl-actin probes. 
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12SI-labeled lysates of  neutrophils 
from one patient with hypereosino- 
philic syndrome  (Neu), and of alve- 
olar macrophages (Me) as control. 
Results were  obtained  with anti-Mac- 
2 hybridoma  supematant  (lanes  a) and 
with normal  rat serum  control  (lanes 
b). The Mr is indicated  in kD. (-,-) 
28-kD molecule. 
tiation and maturation, such as in HL60 differentiated to mac- 
rophages (6) or in different mast cell lines (18).  The varia- 
tions in Mac-2 mRNA denoted in patients suggest that, in 
some diseases, neutrophils could be in different stages of matu- 
ration,  leading  therefore  to  higher  expression  of Mac-2 
mRNA. Our results indicate that neutrophils did not seem 
to express CD23 mRNA, but have the capacity to synthe- 
size Mac-2/eBP mRNA,  although in lower amounts than 
eosinophils (Truong, M. J., et al., manuscript submitted for 
publication). 
Characterization of Mac-2/eBP Molecules by Immunoprecipi- 
ration.  To characterize the translation products of  Mac-2/eBP 
mKNA detected above, immunoprecipitation by anti-Mac-2 
hybridoma supernatant (Fig.  2,  lanes a) or control (Fig.  2, 
lanes b) was performed with neutrophil extract from one rep- 
resentative patient (Neu) and with alveolar macrophage ex- 
tract (Me). Similarly to results obtained with macrophages, 
the 28-kD molecule could be detected in human neutrophils. 
Based upon these results, it was concluded that human neu- 
trophils have the capacity to express Mac-2/eBP, previously 
detected in a variety of cell types such as macrophages, mast 
cell lines,  and eosinophils (6,  7,  10,  18). 
Flaw Cytometry  Analysis of  Mac-2 Surface  Expression  and leE- 
binding Capacity.  The detection of Mac-2/eBP by Northern 
blot and by immunoprecipitation led us to investigate their 
surface expression on neutrophils, by flow cytometry (Table 
1). In comparison to Fc~R.II/CD23, which was not detected 
on neutrophils, a finding in agreement with Northern blot 
results, surface Mac-2 molecules were expressed on a significant 
percentage of neutrophils purified from patients as well as 
from normal donors. Since Mac-2/eBP lectins have the ca- 
pacity to bind to carbohydrate determinants of IgE (5,  7), 
we have evaluated the binding of IgE to neutrophils by flow 
cytometry (Table  1).  When myeloma IgE-PS was  used,  a 
significant correlation was obtained between the expression 
of Mac-2 and the binding of IgE-PS, both for patients (r  = 
0.57; p <0.01) and for normal donors (r  =  0.56; p  <0.05), 
suggesting that IgE-PS could bind to Mac-2 expressed on 
neutrophil surface.  Increased IgE binding was observed in 
the case of neutrophils  from patients,  which also  showed 
similar increased binding of IgA, known to bind to neutro- 
phils (19). These findings, already described for eosinophils 
(8) could be related to the state of activation of neutrophils 
from patients. It is interesting that the IgE-binding capacity 
of neutrophils from all donors varied according to the my- 
eloma IgE tested (Table 1). A significantly lower percentage 
of neutrophils bound to  IgE-BL in comparison to IgE-PS 
(p <0.001).  This result was surprising since it has been pre- 
viously reported that myeloma IgE-PS was poorly recognized 
by Mac-2/eBP (7). A comparative analysis between the two 
IgE-PS preparations (one provided by Dr. Ishizaka, La Jolla 
Institute Allergy and Immunology, La Jolla,  CA) and the 
other by Dr.  Spiegelberg) has been performed, and results 
indicate that the IgE-PS used in the present work was better 
recognized by eBP,  a  finding probably reflecting different 
glycosylation between the two IgE preparations (Dr. F.-T. 
Liu, personal communication). 
Table  1.  Flow  Gytometry Analysis of Membrane Expression of CD23, Mac-2, IgE- and IgA-binding Molecules 
Percent positive cells~ 
Source of neutrophils*  CD23  Mac-2  IgE-PS  IgE-BL  IgA 
Patients  2.1  _+ 0.8  40.1  _+  4.7  40.1  +  5.9  9.7  _+  3.6  52.9  _+  13.6 
Normal donors  2.3  +  1.2  54.6  _+  5.6  27.9  _+  8.0  13.8  _+ 4.2  33.3  +  5.9 
" Neutrophils were purified from patients (n  =  16) or from normal donors (n  =  10). 
* Neutrophils were incubated with 50/zg/ml anti-CD23 8-30 mAb, myeloma  IgE (IS or BL), serum IgA, or anti-Mac-2 hybridoma  supernatant 
(dilution 1:10), before  staining  with the corresponding  FITC-conjugated  anti-lg antibodies. The percentage  of positive cells  was obtained  after sub- 
traction of the nonspecific  binding with the control antibody or medium (mean _+ SEM). 
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Percent  positive ceils* 
Treatment  of Ig  IgE-PS  IgE-BL  IgA 
None  58.7  +_ 8.1  16.8  +  2.1  47.3  _+ 7.9 
NeuraminidaseI  79.5  _+ 4.4  55.7  ,+  5.1  50.1  +  8.5 
Heat-inactivated  neuraminidasel  60.7  +  5.9  22.5  ,+  4.0  52.7  _+  11.6 
* Neutrophils were incubated with 50 pg/ml IgE-PS, IgE-BL, or serum IgA and stained with the corresponding FITC-labeled anti-Ig (mean of 
4-11 experiments + SEM). 
t The various Ig have been treated with neuraminidase (0.03 U/ml)  for 90 min at 37"C before incubation with neutrophils. 
s Neuraminidase was heat-inactivated for 1 h at 56"C before incubation with Ig. 
In relation to the fact that Mac-2/eBP could bind to re- 
stricted IgE glycoforms, experiments were performed with 
the same myeloma IgE proteins previously treated with neur- 
aminidase (Table 2). A significant increase in IgE binding was 
observed both for IgE-PS and for IgE-BL, but more pro- 
nounced for the latter. In contrast, neuraminidase treatment 
did not affect the binding of serum IgA to nentrophils, which 
occurs through the myeloid FcottL (19). It has to be noticed 
that the effect of neuraminidase on IgE-BL binding was abol- 
ished after heat inactivation.  It was concluded that neutro- 
phils can bind some IgE glycoforms likely through  surface 
Mac-2/eBP and not through transmembrane CD23. In con- 
trast to eosinophils which express both CD23 epitopes (17) 
and Mac-2/eBP (10) and which therefore can bind myeloma 
IgE independently of their degree of glycosylation, neutro- 
phils seem to express only molecules of the S-type lectin family 
with IgE recognition modulated by sialylation of IgE oligosac- 
charides. 
Neutrophil  Activation  by Myeloma  or Polyclonal lgE.  The 
function of IgE-binding molecules expressed on neutrophil 
surface has been investigated in an experimental assay mea- 
suring the respiratory burst by CL. After preliminary dose- 
dependence studies, we could show that incubation of neu- 
trophils  with  10/~g/ml  of IgE or IgA and then with  the 
corresponding anti-Ig antibodies,  induced a luminol-dependent 
CL reaction. As shown in Fig. 3 A, only myeloma IgE-PS, 
but not IgE-BL, induced a CL level dose to that  induced 
by serum IgA, as positive control (19). In addition, the mag- 
nitude order of IgE-PS- and IgA-dependent respiratory burst 
was significantly higher for neutrophils from patients than 
from normal donors. These results were in agreement with 
IgE-PS- and IgA-binding observed by flow cytometry (Table 
1). Unfortunatdy, CL experiments with neuraminidase-treated 
Ig  could  not  be performed  since  neuraminidase  by itself 
nonspecifically inhibited  the CL production. 
To know whether, in addition to myeloma IgE, polyclonal 
IgE with or without antibody specificity could also induce 
nentrophil activation, neutrophils were incubated either with 
the serum from patients with hyper-IgE syndrome or from 
schistosomiasis-infected patients (Fig. 3 B). The former sera, 
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Figure 3.  IgE-dependent  activation of neutrophils from individual donors measured  by CL. (.4). CL of neutrophils purified from hypereosinophilic 
patients (associated  or not with parasitic infections or allergic disease) and from normal donors by incubation with 10/~g/ml myeloma IgE (IgE-PS 
and IgE-BL) or serum IgA, and 25/~g/ml anti-IgE or anti-IgA antibodies. (B). Normal donors' neutrophil CL induced by anti-IgE (g~) or Sm28GST 
Ag (Ira) with: sera from two patients with hyper-IgE syndrome (I and 2) which contained 8,000 IU/ml IgE; and sera from four different patients 
with schistosomiasis  (1-4). Normal human serum (NHS), Sm28GST, and anti-IgE alone (M) represented the controls. (C) Normal donors' neutrophil 
CL induced by different concentrations of pooled sera from schistosomiasis  patients (P -  1, 3, and 4). The evaluation of CL was calculated as described 
in Materials and Methods. 
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Figure  4.  Dose-effect of anti-Mac-2 supernatant on myeloma IgE-PS 
(-l~) and IgA (+) dependent  CL, on pool  P (polyclonal  IgE)-dependent 
activation induced  by Sm28GST (-O-) or anti-IgE (--A-) on normal 
donors'  neutrophils.  The percent  CL inhibition  was calculated  by compar- 
ison to results obtained  with control  used at the same concentrations,  as 
described in Materials and Methods. 
previously shown to bind to Sepharose-linked  heBP (7), in- 
duced a variable respiratory burst in the presence of anti-IgE 
varying with neutrophil donors and with patient sera. In the 
case of schistosomiasis  patient sera, the incubation with specific 
antigen Sm28GST as well as with anti-IgE antibodies induced 
a respiratory burst (Fig. 3 B). No CL was produced when 
only serum, antigen Sm28GST, or anti-IgE alone was added 
to neutrophils. These results indicate that after cross-linking 
with antigen or anti-IgE, specific IgE antibodies can induce 
a respiratory burst in nentrophils. Sera from three schistosomi- 
asis patients were pooled (P, sera 1, 3, and 4) and the pool 
was shown to induce a dose-dependent CL reaction, in the 
presence of either specific antigen Sm28GST or anti-IgE (Fig. 
3 C). The 1:100 dilution was selected for further experiments. 
Role of  Mac-2/eBP in IgE.dependent Neutrophil Activation.  To 
identify the nature of the molecules involved in IgE-dependent 
activation of neutrophils, inhibition procedures with various 
antibodies were performed (Fig. 4). In the case of activation 
with myeloma IgE and anti-IgE antibodies, a dose-dependent 
inhibition of CL was observed with anti-Mac-2  hybridoma 
supernatant, in comparison to control supernatant. In con- 
trast, anti-Mac-2  antibodies showed no significant effect on 
IgA-dependent activation. 
The involvement of Mac-2 was also investigated in neu- 
trophil activation induced by polydonal IgE antibodies. Ac- 
cording to the stimulus (Sm28GST or anti-IgE), a significant 
dose-dependent inhibition of neutrophil respiratory burst was 
obtained with anti-Mac-2 mAb (Fig. 4). No significant inhi- 
bition was induced by anti-CD23 mAb for a concentration 
of 50/zg/ml in the case of Sm28GST antigen or anti-IgE 
stimulations (14.8 and 0% inhibition, respectively).  It has 
to be noticed that no CL was produced after incubation of 
neutrophils with anti-Mac-2 or anti-CD23 mAb either alone 
or after cross-linking with antiisotype antibodies. Based upon 
these results, Mac-2 molecules but not CD23, appeared in- 
volved in IgE-dependent activation of human neutrophils. 
Taken together, the present results suggest that human neu- 
trophils from patients with various diseases, but also from 
normal donors, could express functional IgE-binding mole- 
cules. Interactions between mouse neutrophils and IgE anti- 
bodies in cytotoxicity assays have been previously reported. 
However, no attempt at characterization of IgE-binding mob 
ecules potentially expressed by neutrophils was made at this 
time (20). The more interesting question in relation to the 
in vivo relevance was certaiuly to know whether neutrophils 
could bind to and be activated by polydonal IgE from pa- 
tients. Our results indicate that not only restricted glyco- 
forms of myeloma IgE proteins but also polyclonal IgE anti- 
bodies could induce nentrophil activation in an antigen-specific 
manner. These findings suggest that in addition to FceR- 
bearing cell populations, neutrophils might participate in IgE- 
dependent reactions.  It remains to be determined whether, 
as for other cell populations, the IgE-dependent activation 
of neutrophils may induce the generation of mediators poten- 
tially involved in inflammatory reactions.  Along the same 
line, further experiments are needed to demonstrate the pos- 
sible implication of neutrophils in the IgE-dependent pro- 
tective immunity against schistosomiasis (21). When com- 
pared  with  eosinophils,  Mac-2  molecules  seemed  to  be 
expressed on the surface of a larger majority of neutrophil 
donors (2 negative out of 16 patients and 3 negative out of 
10 normal donors), whereas Mac-2 was expressed on the sur- 
face of only half of HE patients (Truong, M. J. et al., manu- 
script submitted for publication). This might indicate a differ- 
ence in the regulatory process of surface expression of these 
endogenous lectins on the two cell populations. Another in- 
teresting difference between nentrophils and eosinophils is 
that only Mac-2, but not CD23, seemed to be expressed and 
was functional on neutrophils, whereas eosinophils possessed 
both types of molecules. This finding probably explains why 
all myeloma IgE proteins could bind to eosinophils (8), ir- 
respective  of their degree of glycosylation, whereas their 
binding to neutrophils was increased after sialidase treatment. 
Thus, it was concluded that neutrophils, similarly to other 
call  populations, might participate in  the  IgE-dependent 
effector phase of various diseases. 
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